Ganglionat

Ganglionated plexus ablation does not prevent atrial fibrillation better than pulmonary vein isolation

Ganglionated plexus ablation did not prevent atrial fibrillation (AF) better than pulmonary vein isolation (PVI), according to a study presented at the Virtual 2021 Annual Meeting of the Heart Rhythm Society (HRS). In a study of 180 patients, Min-Young Kim, MD, Imperial College London, London, United Kingdom, and colleagues found no significant difference in freedom from atrial arrhythmia lasting more than 30 seconds in the PVI arm (64%) compared with the ganglionated plexus ablation arm (50%) at 12 months (P = .09). The rate of redo ablations was similar for the 50 patients in the PVI a...

Studies examine antibody response in kidney transplant recipients and haemodialysis patients wh...

A study published in JAMA found that a third dose of mRNA-1273 (Moderna) vaccine induced a serologic...

Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients...

BACKGROUND Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) pa...


Suggested videos

Search:
Date
Filters:
Abelacimab
13:53

Abelacimab for Prevention of Venous Thromboembolism

Presenter: Jeffrey Weitz
Hematology
ISTH 2021
Expanded e
10:42

Expanded efficacy and safety data from CheckMate 649

Presenter: Markus Moehler
Oncology
ASCO 2021
Current st
8:18

Current state of frontline immunotherapy options in the treatment of NSCLC

Presenter: Federico Cappuzzo
Oncology
ASCO 2021
The QUAZAR
13:56

The QUAZAR AML-001 Maintenance Trial

Presenter: Eytan Stein
Hematology
EHA 2021
Important
8:39

Important messages from EULAR2021: Impact of air pollution on RA flares, effect of COVID-19 on RA care, osteoporosis care of men

Presenter: Giovanni Adami
Internal Medicine
EULAR 2021
Balancing
13:20

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma studies

Presenter: Jeanny B. Aragon-Ching
Urology
EAU 2021
Clinical d
9:37

Clinical decision making in the treatment of melanoma

Presenter: Paolo A. Ascierto
Oncology
ASCO 2021
State of t
7:15

State of the art treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
ASCO 2021
State of t
5:21

State of the art treatment of breast cancer

Presenter: Virginia G. Kaklamani
Oncology
ASCO 2021
State of t
17:01

State of the art treatment of multiple myeloma

Presenter: Andrzej Jakubowiak
Oncology
ASCO 2021
Current st
13:02

Current state of immunotherapy options in the treatment of RCC

Presenter: Camillo Porta
Oncology
ASCO 2021
Idecabtage...
10:25

Idecabtagene vicleucel, a BCMA-​directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma

Presenter: Albert Oriol
Hematology
EHA 2021
Novelties
7:52

Novelties in the treatment of Multiple Myeloma

Presenter: Enrique Ocio
Hematology
EHA 2021
Effect of
12:51

Effect of first-line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status.

Presenter: Rajwanth Veluswamy
Oncology
ASCO 2021
Current st
11:17

Current state of immunotherapy options in the treatment of melanoma

Presenter: Jeffrey Weber
Oncology
ASCO 2021
Treatment
9:31

Treatment of hematological malignancies in 2021

Presenter: Paolo Corradini
Hematology
EHA 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology